Skip to Content

Itamar Medical: New fee schedule advances WatchPAT

Itamar Medical: New fee schedule advances WatchPAT

CAESAREA, Israel - The recently released 2019 fee schedule from CMS should support broad use of Itamar Medical's WatchPAT technology, the company says. WatchPAT uses peripheral arterial tone (PAT) technology to provide cardiologists and sleep physicians in the United States with accurate sleep diagnoses. “We believe that the new CMS fee schedule validates the clinical value of our sleep tests for patients and may significantly advance utilization of our sleep tests in the U.S. market,” said Gilad Glick, CEO of Itamar Medical. “It also reflects growing awareness of deploying home sleep apnea testing and sleep apnea management as essential components of the cardiology care pathway.” Itamar Medical estimates that WatchPAT technology accounted for about 15% of the home sleep tests in the U.S. in 2017.

Comments

To comment on this post, please log in to your account or set up an account now.